CHEMM ChemoMetec

Guidance for the 2025/26 financial year

Guidance for the 2025/26 financial year

ANNOUNCEMENT NO. 291

11 September 2025



Guidance for the 2025/26 financial year 

ChemoMetec today approved the annual report for 2024/25, including the guidance for 2025/26, which is considered inside information.

For 2025/26, ChemoMetec expects revenue in the range of DKK 545-565 million (2024/25: DKK 495.6 million) and EBITDA in the range of DKK 295-315 million (2024/25: DKK 258.0 million).

The annual report for 2024/25, which is released along with this announcement, sets out the underlying assumptions applied in the preparation of the guidance for 2025/26 (p. 39-40).



Additional information

Martin Helbo Behrens, CEO

Tel.: (+45) 48 13 10 20

Kim Nicolajsen, CFO

Tel.: (+45) 48 13 10 20

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to .



EN
11/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ChemoMetec

ChemoMetec A S: 2 directors

Two Directors at ChemoMetec A S bought 1,817 shares at between 684.000DKK and 704.000DKK. The significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...

 PRESS RELEASE

Indberetning af ledende medarbejderes transaktioner

Indberetning af ledende medarbejderes transaktioner MEDDELELSE NR. 298 7. november 2025 Indberetning af ledende medarbejderes transaktioner ChemoMetec A/S har i henhold til artikel 19 i forordning (EU) nr. 596/2014 modtaget nedenstående indberetning om transaktioner i ChemoMetec A/S aktier udført af personer med ledelsesansvar og/eller personer, der er nært knyttet til dem. Se indberetning af CFO Kim Nicolajsens transaktioner i vedhæftede pdf-dokument. Yderligere oplysninger kan fås ved henvendelse til: Kim Nicolajsen, CFOTelefon: (+45) 48 13 10 20           Om ChemoMetec A/S Chemo...

 PRESS RELEASE

Notification of managers’ transactions

Notification of managers’ transactions ANNOUNCEMENT NO. 298 7 November 2025 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of CFO Kim Nicolajsen in the attached PDF document. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45) 48 13 10 20 About ChemoMetec A/S ChemoMetec dev...

 PRESS RELEASE

Indberetning af ledende medarbejderes transaktioner

Indberetning af ledende medarbejderes transaktioner MEDDELELSE NR. 297 7. november 2025 Indberetning af ledende medarbejderes transaktioner ChemoMetec A/S har i henhold til artikel 19 i forordning (EU) nr. 596/2014 modtaget nedenstående indberetning om transaktioner i ChemoMetec A/S aktier udført af personer med ledelsesansvar og/eller personer, der er nært knyttet til dem. Se indberetning af administrerende direktør Martin Helbo Behrens’ transaktioner i vedhæftede pdf-dokument. Yderligere oplysninger kan fås ved henvendelse til: Kim Nicolajsen, CFOTelefon: (+45) 48 13 10 20         ...

 PRESS RELEASE

Notification of managers’ transactions

Notification of managers’ transactions ANNOUNCEMENT NO. 297 7 November 2025 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of CEO Martin Helbo Behrens in the attached PDF document. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45) 48 13 10 20 About ChemoMetec A/S ChemoMet...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch